AU2019410062A1 - Combination treatment for solid tumors using docetaxel and a CYP3A inhibitor - Google Patents

Combination treatment for solid tumors using docetaxel and a CYP3A inhibitor Download PDF

Info

Publication number
AU2019410062A1
AU2019410062A1 AU2019410062A AU2019410062A AU2019410062A1 AU 2019410062 A1 AU2019410062 A1 AU 2019410062A1 AU 2019410062 A AU2019410062 A AU 2019410062A AU 2019410062 A AU2019410062 A AU 2019410062A AU 2019410062 A1 AU2019410062 A1 AU 2019410062A1
Authority
AU
Australia
Prior art keywords
docetaxel
cyp3a
cyp3a inhibitor
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019410062A
Other languages
English (en)
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modra Pharmaceuticals BV
Original Assignee
Modra Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals BV filed Critical Modra Pharmaceuticals BV
Publication of AU2019410062A1 publication Critical patent/AU2019410062A1/en
Priority to AU2023204693A priority Critical patent/AU2023204693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019410062A 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a CYP3A inhibitor Abandoned AU2019410062A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023204693A AU2023204693A1 (en) 2018-12-21 2023-07-14 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18215488.0 2018-12-21
EP18215488 2018-12-21
PCT/EP2019/086125 WO2020127607A1 (en) 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023204693A Division AU2023204693A1 (en) 2018-12-21 2023-07-14 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Publications (1)

Publication Number Publication Date
AU2019410062A1 true AU2019410062A1 (en) 2021-08-12

Family

ID=64901398

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019410062A Abandoned AU2019410062A1 (en) 2018-12-21 2019-12-18 Combination treatment for solid tumors using docetaxel and a CYP3A inhibitor
AU2023204693A Abandoned AU2023204693A1 (en) 2018-12-21 2023-07-14 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023204693A Abandoned AU2023204693A1 (en) 2018-12-21 2023-07-14 Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Country Status (13)

Country Link
US (1) US20220071944A1 (enExample)
EP (1) EP3897611A1 (enExample)
JP (3) JP2022514960A (enExample)
KR (1) KR20220004011A (enExample)
CN (1) CN113473982A (enExample)
AU (2) AU2019410062A1 (enExample)
BR (1) BR112021012266A2 (enExample)
CA (1) CA3124319C (enExample)
CL (1) CL2021001635A1 (enExample)
IL (1) IL284225A (enExample)
MX (1) MX2021007480A (enExample)
PE (1) PE20220129A1 (enExample)
WO (1) WO2020127607A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021012255A2 (pt) * 2018-12-21 2021-09-28 Modra Pharmaceuticals B.V. Método para o tratamento de um câncer em um paciente, método para reduzir efeitos colaterais do tratamento de um câncer em um paciente, combinação de um inibidor de cyp3a e docetaxel para uso em um tratamento médico de um câncer, docetaxel para uso em uma terapia de combinação no tratamento de câncer, inibidor de cyp3a para uso em uma terapia de combinação no tratamento de câncer, uso e kit que compreende uma composição farmacêutica para administração oral que compreende docetaxel e uma composição farmacêutica que compreende um inibidor de cyp3a
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients
CN116270617B (zh) * 2023-03-29 2024-01-26 济宁医学院附属医院 Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101544498B1 (ko) * 2007-08-24 2015-08-17 스티칭 허트 네덜란드 칸커 인스티튜트 종양성 질환의 치료를 위한 조성물
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
EP2328555A2 (en) 2008-08-22 2011-06-08 Slotervaart Participaties BV Compositions for the treatment of neoplastic diseases
BR112021012255A2 (pt) * 2018-12-21 2021-09-28 Modra Pharmaceuticals B.V. Método para o tratamento de um câncer em um paciente, método para reduzir efeitos colaterais do tratamento de um câncer em um paciente, combinação de um inibidor de cyp3a e docetaxel para uso em um tratamento médico de um câncer, docetaxel para uso em uma terapia de combinação no tratamento de câncer, inibidor de cyp3a para uso em uma terapia de combinação no tratamento de câncer, uso e kit que compreende uma composição farmacêutica para administração oral que compreende docetaxel e uma composição farmacêutica que compreende um inibidor de cyp3a

Also Published As

Publication number Publication date
WO2020127607A1 (en) 2020-06-25
US20220071944A1 (en) 2022-03-10
EP3897611A1 (en) 2021-10-27
AU2023204693A1 (en) 2023-08-10
MX2021007480A (es) 2021-10-13
CL2021001635A1 (es) 2022-04-22
BR112021012266A2 (pt) 2021-08-31
JP2023102786A (ja) 2023-07-25
CN113473982A (zh) 2021-10-01
CA3124319C (en) 2023-07-04
CA3124319A1 (en) 2020-06-25
JP2025094186A (ja) 2025-06-24
PE20220129A1 (es) 2022-01-27
IL284225A (en) 2021-08-31
KR20220004011A (ko) 2022-01-11
JP2022514960A (ja) 2022-02-16

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
AU2023204693A1 (en) Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
US20240091194A1 (en) 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients
KR20200026969A (ko) 치료제의 비경구 투여를 위한 조성물
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
TW202337469A (zh) 治療小細胞肺癌之方法
EP3854396A1 (en) Quinoline derivative used for treating small cell lung cancer
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
CN118946350A (zh) 用于治疗紫杉烷耐药性患者的癌症的方法和组合物

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted